Urologix, LLC. develops, manufactures and markets minimally invasive office-based BPH therapies for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Since the introduction of office-based therapies nearly 20 years ago, these two technologies have consistently demonstrated safe, efficacious and durable results for patients. Urologix, the market leader and most trusted name in minimally invasive BPH therapies, is proud to offer Cooled ThermoTherapy™ (CTT) and Prostiva® RF Therapy (Prostiva). These two technologies provide Urologists the versatility to treat the majority of prostate anatomies in the office, and provide clinically significant symptom score and flow rate improvement without need for re-treatment in over 90% and 86% of patients, respectively through 5 years.1,2
Watch the Urologix “Our Story” video to learn more about the history and culture of our company.
Urologix has a two-decade track record of providing long-lasting BPH relief to patients who desire an alternative to chronic medication.
Improving quality of life, one patient at a time, as the urologist’s trusted partner to realize the full potential of in-office, evidence-based technologies.
We develop and deliver innovative in-office technologies, best-in-class training and excellent customer service, with a focus on BPH leadership. Success is superior patient outcomes, physician satisfaction and healthcare value.
1Mynderse, L., et al, 5 year Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH, Journal of Urology, May 2001 2Hill, B., et al Transurethreal Needle Ablation vs TURP for the Treatment of Symptomatic BPH: 5 Year Results of a Prospective, Randomized, Multicenter Clinical Trial, Journal of Urology Vol 171, 2336-2340, June 2004